Sanofi

Rilzabrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria unresponsive to antihistamines, in a phase 2 study.

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in patients ages 12 and older with CSU.

Investigational tanrupubart was safe, effective in GBS

Korean randomized trial shows hard endpoint benefit without a difference in bleeding

Machine learning is driving efforts to classify MS into distinct subtypes that may predict disease course, but two experts debate whether this will advance patient care.

Yes, study suggests, but results may not represent a meaningful impact, expert says

Post-treatment, most kids on omalizumab tolerated allergenic foods

Sticker price of blockbuster drug needs to be cut by 46% to reach willingness-to-pay thresholds

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ulcerative colitis as well as in those with Crohn's disease.

Findings suggest possible benefits of ICI therapy on field cancerization, researchers say

/PRNewswire-PRWeb/ -- The International Society of Pharmaceutical Engineering (ISPE) has announced the 2025 Facility of the Year submission finalists. Each of...

Dazukibart targets specific molecular pathology of chronic systemic autoimmune disease

Fluoride helps prevent cavities when applied topically to the teeth, but when ingested can pose significant risks, even kill young children, per new lawsuits.

A new computational technique allows large language models to predict antibody structures more accurately. The work could enable researchers to sift through millions of possible antibodies to identify those that could be used to treat SARS-CoV-2 and other infectious diseases.

Study results are 'historic,' expert says

Rilzabrutinib specifically designed to reduce platelet-targeting autoantibodies

High-fiber diets tied to improved outcomes in stem-cell transplants, slowing myeloma precursors

A new study suggests that 40% of American adults have conditions that could benefit from semaglutide treatment.

A study using a Korean database found that COVID-19 infection raised long-term risks for various autoimmune and autoinflammatory skin disorders, and vaccination may reduce these risks.

Patients with GPA completely weaned off glucocorticoids were four times as likely to flare compared with those kept on a low dose, though these flares were minor.